Qiming Medical-B (02500.HK) announces the mid-term clinical results of the TARGET study on the innovative Cardiovalve transcatheter valve replacement system.

Zhtng Cijng APP News, Qmng Ylio-B (02500.HK) issued an announcement on the mid-term clinical results of the company's innovative transvalvular valve replacement system Cardiovalve in the TARGET study. The TARGET study is a prospective, single-group, multicenter clinical study aimed at evaluating the safety and clinical performance of Cardiovalve transvalvular valve replacement system. The mid-term clinical trial data of the TARGET study includes 125 patients from 25 clinical centers in Germany, Spain, Italy, Canada, and the United Kingdom, with an average age of 77 years old.